{
    "clinical_study": {
        "@rank": "31954", 
        "acronym": "ZODIAC-39", 
        "arm_group": {
            "arm_group_label": "Patients on metformin mono-therapy who receive add-on"
        }, 
        "brief_summary": {
            "textblock": "Next to HbA1c, body weight is regarded as an important surrogate end-point in trials\n      investigating glucose-lowering agents. An increase in weight could contribute to worsening\n      insulin resistance. Differences in weight after starting glucose lowering agents have been\n      described in many randomized controlled trials (RCTs).\n\n      With this prospective observational study, weight trajectories after receiving add-on\n      therapy next to metformin are evaluated in primary care patients with good glycaemic\n      control."
        }, 
        "brief_title": "Weight Trajectory in New Users of Sulfonylureas as Add on Therapy Next to Metformin.", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "This prospective cohort study is part of the ZODIAC (Zwolle Outpatient Diabetes project\n      Integrating Available Care) study, which started in 1998 as a prospective observational\n      study and includes patients with known T2DM who are treated in primary care.\n\n      The investigators aim to investigate the course of the bodyweight and glycaemic control, the\n      years after starting specific SU's, pioglitazone or insulin as add-on therapy, in metformin\n      treated primary care patients with T2DM.\n\n      As part of the process called benchmarking, a dataset of quality measures is collected\n      annually for all patients participating in the ZODIAC study during the patient's visit to\n      the practice nurse and/or general practitioner and sent to the investigators' diabetes\n      centre for benchmarking and research purposes once a year."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  T2DM\n\n          -  Treated in primary care in period 1998 to 2012\n\n          -  used metformin monotherapy\n\n          -  subsequently received add-on therapy with a SU or pioglitazone during their entire\n             follow-up period"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with T2DM who received monotherapy with metformin and needed treatment\n        intensification by receiving add-on therapy next to metformin"
            }
        }, 
        "enrollment": {
            "#text": "4000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02133118", 
            "org_study_id": "ZODIAC"
        }, 
        "intervention": {
            "arm_group_label": "Patients on metformin mono-therapy who receive add-on", 
            "intervention_name": "individual SUs, insulin, pioglitazone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Pioglitazone", 
                "Metformin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Type 2 diabetes", 
            "New-user design", 
            "Weight trajectory", 
            "Add-on therapy", 
            "Sulphonylureas."
        ], 
        "lastchanged_date": "May 6, 2014", 
        "location": {
            "contact": {
                "email": "g.w.d.landman@isala.nl", 
                "last_name": "GWD Landman, Md PhD", 
                "phone": "+31 38 424 50 00"
            }, 
            "contact_backup": {
                "email": "p.r.van.dijk@isala.nl", 
                "last_name": "PR van Dijk, MD", 
                "phone": "+31 38 4247942"
            }, 
            "facility": {
                "address": {
                    "city": "Zwolle", 
                    "country": "Netherlands", 
                    "state": "Overijssel", 
                    "zip": "8000 AB"
                }, 
                "name": "Isala"
            }, 
            "investigator": {
                "last_name": "GWD Landman, MD PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Prospective Observational Cohort Study; The Weight Trajectory in New Users of Sulfonylureas as Add on Therapy Next to Metformin.", 
        "overall_contact": {
            "email": "g.w.d.landman@isala.nl", 
            "last_name": "Gijs Landman, Md PhD", 
            "phone": "+31 38 424 50 00"
        }, 
        "overall_official": [
            {
                "affiliation": "Isala, Diabetes Centre", 
                "last_name": "G. W.D. Landman, MD PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Isala, Diabetes Centre", 
                "last_name": "R. Wever, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Isala, Diabetes Centre", 
                "last_name": "P. R. van Dijk, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Diabetes Centre, Isala, Zwolle", 
                "last_name": "Nanne Kleefstra, MD PhD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Netherlands: Medical Ethics Review Committee (METC)", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The course of the bodyweight up to five years after starting individual SU's (gliclazide/glibenclamide/tolbutamide/glimepiride), pioglitazone or insulin as add-on therapy, in metformin treated primary care patients with T2DM.", 
            "measure": "The course of weight (Kg) after starting individual SU's, pioglitazone or insulin as add-on therapy.", 
            "safety_issue": "No", 
            "time_frame": "Up to 5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02133118"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Medical Research Foundation, The Netherlands", 
            "investigator_full_name": "Gijs Landman", 
            "investigator_title": "MD, PHD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "The course of the glycaemic control, up to five years after starting individual SU's (gliclazide, glibenclamide, tolbutamide, glimepiride), pioglitazone or insulin as add-on therapy, in metformin treated primary care patients with T2DM.", 
            "measure": "The course of the glycaemic control (HbA1c %) , up to five years after starting individual SU's, pioglitazone or insulin as add-on therapy.", 
            "safety_issue": "No", 
            "time_frame": "Up to 5 years"
        }, 
        "source": "Medical Research Foundation, The Netherlands", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medical Research Foundation, The Netherlands", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 1998", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "5 Years", 
        "verification_date": "May 2014"
    }
}